Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people’s lives better by making high quality medicines more accessible around the world.
The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.
Location: United States, New Jersey, Montville Township
Employees: 1001-5000
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | CVC Capita... | cvc.com |
Mentions in press and media 4
| Date | Title | Description | Source |
| 18.04.2024 | NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasda... | The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq St... | salamancap... |
| 01.04.2024 | NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and... | Four potential near-term milestones, including data from two clinical trials, an NDA filing and an u... | salamancap... |
| 26.09.2017 | Term Sheet — Tuesday, September 26 | FRESH FUNDING Good morning, Term Sheet readers. Paid Content What you need to know about growing cyb... | fortune.co... |
| 22.06.2015 | CVC, Temasek team up to buy $2b generic drugs firm Alvogen | Premium A consortium of investors led by private equity firm CVC Capital Partners, that includes Sin... | dealstreet... |